PDCD1 and Miyoshi myopathy: Thus, we studied the patient characteristics and survival outcomes of a retrospective cohort of patients from a single U.S. institution diagnosed with AM or MM who received treatment with FDA‐approved single‐agent anti‐PD‐1 (nivolumab or pembrolizumab) therapy as the standard of care for metastatic or unresectable disease.